Roche lung cancer drug success adds to pressure on Bristol

By Ben Hirschler COPENHAGEN (Reuters) – Lung cancer patients on Roche’s immune system-boosting drug Tecentriq lived on average 4.2 months longer than those taking chemotherapy in a pivotal study, pressuring Bristol-Myers Squibb’s dominant position in the field. The trial involved second-line patients, who have already used chemotherapy, and it found the Roche drug worked even […]